Costs and effectiveness of treatment alternatives for proximal caries lesions

Abstract

Objectives: Invasive therapy of proximal caries lesions initiates a cascade of re-treatment cycles with increasing loss of dental hard tissue. Non- and micro-invasive treatment aim at delaying this cascade and may thus reduce both the health and economic burden of such lesions. This study compared the costs and effectiveness of alternative treatments of proximal caries lesions.

Methods: A Markov-process model was used to simulate the events following the treatment of a proximal posterior lesion (E2/D1) in a 20-year-old patient in Germany. We compared three interventions (non-invasive; micro-invasive using resin infiltration; invasive using composite restoration). We calculated the risk of complications of initial and possible follow-up treatments and modelled time-dependent non-linear transition probabilities. Costs were calculated based on item-fee catalogues in Germany. Monte-Carlo-microsimulations were performed to compare cost-effectiveness of non- versus micro-invasive treatment and to analyse lifetime costs of all three treatments.

Results: Micro-invasive treatment was both more costly and more effective than non-invasive therapy, with ceiling-value-thresholds for willingness-to-pay between 16.73 € for E2 and 1.57 € for D1 lesions. Invasive treatment was the most costly strategy. Calculated costs and effectiveness were sensitive to lesion stage, patient's age, discounting rate and assumed initial treatment costs.

Conclusions: Non- and micro-invasive treatments have lower long-term costs than invasive therapy of proximal lesions. Micro-invasive therapy had the highest cost-effectiveness for treating D1 lesions in young patients. Decision makers with a willingness-to-pay over 16.73 € and 1.57 € for E2 and D1 lesions, respectively, will find micro-invasive treatment more cost-effective than non-invasive therapy.

Conflict of interest statement

Competing Interests: The authors have read the journal’s policy and have the following conflicts: HML and SP are appointed as inventors US and European patents for an infiltration technique for dental caries lesions, held by Charité-Universitätsmedizin Berlin, and receive royalties from DMG. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials. The following are the patents in more detail, including the country code, the patent number, and the patent’s title. US - US 11/040,442 - Salzsäuregel und Infiltrat zur Versiegelung von kariösen Läsionen; WO/US - US 12/300,437 - Infiltration zur Penetration von Karies; WO/EP - EP 07725124.7 - Infiltration zur Penetration von Karies; WO/KR – KR - Infiltration zur Penetration von Karies; WO/RU – RU - Infiltration zur Penetration von Karies; WO/JP - JP 2009-508257 - Method and means of infiltrating enamel lesions; WO/JP - JP 2009536633 - Infiltration zur Penetration von Karies; WO - PCT/EP2007/004204 - Infiltration zur Penetration von Karies; WO/CN - CN 200780013643.8 - Infiltration zur Penetration von Karies; US - US 11/432,271 - Infiltration zur Penetration von Karies; WO/BR - BR PI07116004 - METODO E MElOS PARA INFILTRACÄO EM LESÖES DO ESMALTE; WO/IN - IN 6789CHENP2008 - Infiltration zur Penetration von Karies; WO/CA - CA 2652045 - METHOD AND MEANS FOR INFILTRATING ENAMEL LESIONS; JP - JP 2013-190681 - Method and means of infiltrating enamel lesions; EP/DE - Method and means for infiltrating enamel lesions; EP/GB - EP 06021966.4 - Method and means for infiltrating enamel lesions; EP/CH - EP 06021966.4 - Method and means for infiltrating enamel lesions; EP/LI - EP 06021966.4 - Method and means for infiltrating enamel lesions; EP/FR - EP 06021966.4 - Method and means for infiltrating enamel lesions; EP/IT - EP 06021966.4 - Method and means for infiltrating enamel lesions; EP - EP 06021966.4 - Method and means for infiltrating enamel lesions; DE - DE 20 2008 006 814.2 - Vorrichtung zum Halten eines Röntgenfilms im Dentalbereich; WO/BR - Vorrichtung zur Infiltration approximaler Schmelzläsionen von Zähnen; WO/KR - KR 20107013471 - Vorrichtung zur Infiltration approximaler Schmelzläsionen von Zähnen; WO/CA - CA 2708491 - DEVICE FOR INFILTRATION OF APPROXIMAL ENAMEL LESIONS OF TEETH; WO/CN - CN 20088121095 - Device for infiltration of approximal enamel lesions of teeth; EP - EP 07024508.9 - Vorrichtung zur Infiltration approximaler Schmelzläsionen von Zähnen; WO - PCT/EP2008/008968 - Vorrichtung zur Infiltration approximaler Schmelzläsionen von Zähnen; WO/JP - JP 2010538376 - Vorrichtung zur Infiltration approximaler Schmelzläsionen von Zähnen; WO/RU - RU 2010129959 - Device for the infiltration of enamel lesions in teeth; WO/EP - EP 08861037.3 - Vorrichtung zur Infiltration approximaler Schmelzläsionen von Zähnen; WO/IN - Vorrichtung zur Infiltration approximaler Schmelzläsionen von Zähnen; WO/US - US 12/808,539 Device for Infiltration of Approximal Enamel Lesions of Teeth

Figures

Figure 1. State-transition diagram.

A Markov-model was used to simulate non-, micro- or invasive treatment of proximal E2 or D1 lesions. Non- and micro-invasively treated E2 lesions remained in their state (circled arrows) or progressed to D1 lesions according to their transition probabilities (Table 1). Translation to the next state accrued costs (Table 2). If D1 lesions progressed further, restoration with composite was simulated. Invasively treated lesions were restored using composite regardless of their stage. Restorations were assumed to fail either due to endodontic complications, requiring endodontic (re-)treatment, or due to restorative complications, requiring repair, recementation or re-restoration. Teeth could always translate to extraction (depending on allocation probabilities or if no further options remained). Missing teeth were replaced in 80% of simulations. Replacement was performed using implant-retained single crowns.

Figure 2. Cost-effectiveness of different treatment strategies.

2a: Cost-effectiveness-planes of non- and micro-invasive treatment of E2 (left) and D1 lesions (right). Horizontal and vertical axes represent effectiveness (% of unrestored lesions over lifetime) and lifetime treatment costs (€), respectively. For non-invasive and follow-up treatments, parameter uncertainty was introduced by random sampling from a triangular distribution within the 95% Confidence Interval. Effects of uncertainty related to micro-invasive treatment were explored using scenario analyses (see Table 3). Non-invasive treatment was less costly and less effective than micro-invasive treatment. Regardless of the initial treatment, progression of E2 lesions occurred at later stages of life and in only few lesions, with low costs for such late re-treatment due to discounting effects. Micro-invasive treatment prevented progression of an additional 4.7% of E2 lesions compared with non-invasive treatment. The low effectiveness gain at high additional costs made micro-invasive treatment less cost-effective for E2 lesions. D1 lesions had higher transition probabilities after both treatments than E2 lesions. Micro-invasive treatment prevented the progression of an additional 27.0% of D1 lesions compared with non-invasive treatment, resulting in a more pronounced effectiveness advantage. 2b: Incremental cost-effectiveness planes. Horizontal and vertical axes illustrate the effectiveness- and cost-differences between micro- compared with non-invasive treatment. The ellipses represent 95% confidence intervals. Micro-invasive treatment was more costly and effective than non-invasive therapy for both E2 (left) and D1 lesions (right). Consequently, all ICERs are found in the north-eastern quadrant. Cost-differences were higher for E2 lesions, whilst effectiveness-differences were higher for D1 lesions.

Figure 3. Cost-acceptability and net-benefit of different treatment strategies.

3a: Cost-effectiveness-acceptability curves. For each strategy, the probability of being cost-effective is plotted against a ceiling value (€). This value reflects the maximum a decision-maker is willing to invest to achieve an additional unit of effectiveness . By increasing the ceiling value, the higher initial treatment costs of micro-invasive therapy become less important and its probability of cost-effectiveness increases. For E2 lesions, both non- and micro-invasive treatment were found to have an equal chance of cost-effectiveness at a threshold of 16.73€. Below this ceiling value, non-invasive treatment would be more likely to be cost-effective, whilst micro-invasive treatment has a higher probability of being cost-effective above that value. This value was reduced to 1.57 € for D1 lesions: These lesions had higher transition probabilities, and micro-invasive treatment prevented progression of considerably more D1 than E2 lesions (27.0% compared with 4.7%) in comparison with non-invasive treatment. This increased effectiveness resulted in a lower ceiling value threshold for D1 compared to E2 lesions. 3b: Net benefit curves. Net benefit of non- and micro-invasive treatment for E2 (left) and D1 lesions (right) depending on the costs for non-invasive therapy was calculated assuming a willingness-to-pay ceiling value of 0 €. If non-invasive therapy was more costly than 5.05 € or 4.63 €, respectively, micro-invasive treatment had the higher net benefit.

Figure 4. Lifetime costs of different treatment strategies.

4a: Costs were analysed within the base-case scenario (20-year old patient, life expectancy 58.25 years, discount rate 3% per year, initial treatment costs for non-, micro- and invasive treatment 0.54 €, 84.99 € and 92.66 €, respectively). Costs for invasively treated lesions were not influenced by lesion stage. Since E2 lesions had lower transition probabilities than D1 lesions, lifetime costs for non- or micro-invasively treated E2 lesions were reduced compared to D1 lesions. Due to reduced efficacy of non-invasive treatment for D1 lesions, the cost-advantage of non-invasive compared to micro-invasive treatment was considerably reduced for these lesions. Invasive treatment was the most expensive option for both E2 and D1 lesions. 4b: Lifetime costs within the high-cost scenario. Non-invasive was assumed to accrue costs of 9.84 € for topical fluoridation each cycle, followed by costs for follow-up treatments. Micro-invasive treatment initially generated costs of 129.33 €, followed by regular costs for topical fluoridation and all follow-up treatments. Invasive treatment was assumed to initially generate costs of 130.19 €, followed by costs for follow-up treatment. Within this scenario, micro-invasive treatment was the least costly treatment for both E2 and D1 lesions.